Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: April 7, 2011
Last updated: July 18, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||December 2020|
|Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|